Clinical trial
Efficacy of Perindopril to Prevent Recurrence of Atrial Fibrillation in Patients…
NCT00461903 · Montreal Heart Institute, Other · Completed
Key facts
| NCT number | NCT00461903 |
|---|---|
| Title | Efficacy of Perindopril to Prevent Recurrence of Atrial Fibrillation in Patients With Essential Hypertension |
| Official title | A Prospective, Randomized, Double-blind Placebo-controlled Study to Determine the Efficacy of 8 mg/Day Oral Perindopril to Prevent the Recurrence of Atrial Fibrillation in Patients With Essential Hypertension |
| Acronym | CTAF-2 |
| Lead sponsor | Montreal Heart Institute, Other |
| Collaborators | Servier Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Essential Hypertension, Atrial Fibrillation |
| Intervention type | Drug |
| Interventions | Perindopril |
| Enrollment | 316 |
| Start date | Dec 1, 2007 |
| Primary completion | Sep 1, 2015 |
| Completion | Sep 1, 2015 |
| First posted | Apr 18, 2007 |
| Last update posted | Feb 21, 2020 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: